BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10365821
• 负责人: Steven J. Fliesler
• 金额: --
• 依托单位: VA WESTERN NEW YORK HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-10-01 至 2026-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10365821
• 关键词: 7-dehydrocholesterol reductase; Ablation; Acoustics; Affect; Afghanistan; Antioxidants; Award; Biochemistry; Biological; Biomedical Research; Blindness; Book Chapters; Brain; Buffaloes; Caring; Categories; Cellular biology; Cerebral cortex; Cholesterol; Cholesterol Homeostasis; Clinical; Collaborations; Communities; Conflict (Psychology); Congenital disorders of glycosylation; Defect; Deficiency Diseases; Development; Devices; Diphosphates; Disease; Dolichol; Educational process of instructing; Enzymes; Equilibrium; Eukaryotic Cell; Exhibits; Explosion; Exposure to; Extramural Activities; Eye; Eye Injuries; Faculty; Foundations; Functional disorder; Funding; Genes; Genetic Diseases; Glial Fibrillary Acidic Protein; Gliosis; Goals; Grant; Grant Review; Human; Human Genetics; Inherited; Injury; Institution; International; International Aspects; Intervention; Investigation; Iraq; Journals; Lateral; Lead; Liquid substance; Medical Students; Mentors; Mission; Modeling; Molecular; Mutation; Nonpenetrating Wounds; Ocular Pathology; Ophthalmology; Participant; Patients; Peer Review; Percussion; Persons; Pharmacology; Photoreceptors; Postdoctoral Fellow; Privatization; Professional Organizations; Proteins; Publications; Publishing; Rattus; Recording of previous events; Regulation; Reporting; Research; Research Personnel; Retina; Retinal Degeneration; Retinitis Pigmentosa; Role; Safety; Science; Scientist; Services; Shock; Site; Smith-Lemli-Opitz Syndrome; Soldier; Source; Sterols; Structure; System; Testing; Therapeutic Intervention; Trauma; Traumatic Brain Injury; Traumatic injury; Tube; United States National Institutes of Health; Universities; Up-Regulation; Veterans; Vision; Vision Disorders; Vision research; Visual; Visual Acuity; Visual Fields; Visual system structure; War; academic standard; blast exposure; career; career development; cell type; cytotoxic; distinguished professor; evidence base; falls; fighting; gene therapy; glycosylation; graduate student; improved; insight; isoprenoid; lectures; legally blind; medical schools; member; mouse model; novel; peer; preservation; prevent; programs; senior faculty; symposium; therapeutic evaluation; therapeutically effective; undergraduate student; visual dysfunction

This is the first competing renewal application for my RCS Award. My lab has been engaged in the field of eye research for >37 years; I’ve been a tenured full Professor since 1994. Historically, our focus has been on understanding the normal role of cholesterol and related isoprenoid compounds in promoting and preserving the structure and function of the retina. However, more recently (during the RCS Award period), we’ve turned to studies relevant to traumatic injury to the eye and visual system. Eye injuries resulting in compromised or lost vision are among the signature injuries sustained by our Veterans and deployed soldiers engaged in the recent conflicts in Iraq and Afghanistan (OEF, OIF). Currently, about 170,000 Veterans are legally blind, and nearly 1.5 million have some kind of visual deficit that is battle-related. Traumatic brain injury (TBI) is another signature injury of those conflicts; a significant percentage of TBI patients suffer visual deficits, nearly a third of which are blast-induced. My lab’s goal is to understand the molecular and cellular mechanisms underlying these kinds of trauma-induced vision loss, and to find practical pharmacological interventions to prevent or retard their progression. Those studies are funded by an ongoing VA MERIT Award. In addition, we’re investigating a form of retinitis pigmentosa (RP59)— a hereditary progressive blinding disorder— about which little is known, initially in an effort to understand the causes of the associated retinal degeneration at the molecular level and eventually to develop gene therapy approaches to ameliorate or prevent the degeneration and vision loss. Those studies are supported by an ongoing NEI/NIH R01 grant award. I’ve been a VA Research Service staff member at the Buffalo VAMC since July, 2008, and an RCSA recipient since April, 2016. I hold a tenured endowed chair Professorship and am Vice-Chair/Director of Research in the Dept. of Ophthalmology at the affiliated university (SUNY- University at Buffalo (UB)). I am the only person in the history of my department to become a UB Distinguished Professor and a SUNY Distinguished Professor, and I am the sole RCSA recipient at my VA site. Over the years, I’ve been fortunate to have numerous, productive collaborations, both with VA and non-VA researchers, including current, ongoing projects, and have a strong history of extramural grant funding. I’ve authored or coauthored 129 peer-reviewed publications (+2 in press, + 2 under review)— 38% of which have been published since I joined the VA— plus 10 book chapters and 242 conference abstracts. I’ve given 241 invited lectures (120 while on VA staff) at other universities and research institutions, plus 65 platform presentations (15 while on VA staff) at biomedical research conferences, nationally and internationally. I’ve engaged in multiple service activities— to the VA (local and national), my university, and the broader research community— including service on VA, NIH, DOD (CDMRP), and private foundation grant review panels. I also serve on the Scientific Advisory Board of Foundation Fighting Blindness (FFB). I’ve been elected President of the two leading international eye and vision research professional societies (ARVO and ISER), and serve as Editor-in-Chief of one of the top two eye research journals (Exp. Eye Res.), as well as serving as a peer reviewer for >4 dozen journals. I teach actively in the Biomedical Sciences Graduate Program of my university, both on scientific topics (Cell Biology and Biochemistry) as well as Responsible Conduct in Research. I’ve mentored numerous undergraduate, graduate, and medical students, as well as postdocs and Ophthalmology Residents in my lab (currently: 2 postdocs, 1 medical student, 1 undergrad). I also actively mentor all junior faculty in my own department (including 2 at my VA site), as well as 22 in other departments within the UB Jacobs School of Medicine and Biomedical Sciences, to assist them in their career development. In addition, I’ve been an active participant in the ARVO Global Mentoring Program, and serve on the ASCB International Affairs Committee. Overall, my research, teaching, and service activities meet or exceed the academic standards of my university and also are fully consistent with the VA HSR&D’s mission and the CRADO’s cross-cutting clinical priorities.

这是我的RCS奖的首次竞争续订申请。我的实验室从事眼球领域 研究> 37年；自1994年以来，我一直是一名终身的完整教授。从历史上看，我们的重点一直在 了解胆固醇和相关类化合物在促进和保存中的正常作用 视网膜的结构和功能。但是，最近（在RCS奖期间），我们转向 与眼睛和视觉系统的创伤性损伤有关的研究。眼睛受伤或丢失的眼睛受伤 视力是我们的退伍军人和部署的士兵所遭受的签名伤害之一 伊拉克和阿富汗的冲突（OEF，OIF）。目前，约有170,000名退伍军人在法律上是盲人，近1.5 百万具有与战斗有关的某种视觉赤字。创伤性脑损伤（TBI）是另一个签名 这些冲突的伤害； TBI患者中有很大一部分患有视觉缺陷，其中几乎三分之一 爆炸引起的。我的实验室的目标是了解这些类型的分子和细胞机制 创伤引起的视力丧失，并找到实用的药物干预措施以防止或阻碍其 进展。这些研究由持续的VA优异奖资助。此外，我们正在调查表格 色素性视网膜炎（RP59） - 一种遗传性进行性盲目疾病 - 最初鲜为人知 为了了解分子水平上相关视网膜变性的原因，最终 开发基因治疗方法以改善或防止退化和视力丧失。这些研究 由正在进行的NEI/NIH R01赠款奖的支持。我是VA研究服务人员 Buffalo VAMC自2008年7月以来，自2016年4月以来是RCSA的收件人。 教授职位和AM副主席/会员大学眼科系研究主任 （布法罗大学的纽约大学（UB））。我是我部门历史上唯一成为UB的人 杰出的教授和纽约州立大学的杰出教授，我是VA网站上的唯一RCSA收件人。 多年来，我很幸运能够与VA和NON-VA进行多次产品合作 研究人员，包括当前的，正在进行的项目，并拥有庞大的校外资助历史。 撰写或撰写了129个同行评审的出版物（+2， + 2， + 2正在评论） - 其中38％ 自从我加入VA以来就出版了 - 加上10章和242次会议摘要。我给了241 邀请其他大学和研究机构的邀请讲座（在VA员工中为120个），以及65个平台 在国内和国际上，在生物医学研究会议上的演讲（在VA员工中为15个）。我 从事多种服务活动 - 向VA（本地和国家），我的大学和更广泛的研究 社区 - 包括VA，NIH，DOD（CDMRP）和私人基金会赠款评论小组的服务。我也是 在基础战斗失明（FFB）的科学顾问委员会任职。我当选为总统 两个领先的国际眼神研究专业社会（Arvo and Iser），并充当 前两个眼研究期刊之一（Exp。Eyeres。）的总编辑，以及担任同行评审者 > 4打期刊。我在大学的生物医学科学研究生课程中积极教授 科学主题（细胞生物学和生物化学）以及负责任的研究行为。我考虑过 许多本科生，研究生和医学生，以及博士后和眼科居民 在我的实验室（目前：2个博士后，1名医学生，1名本科生）。我还积极指导我的所有初级教师 自己的部门（包括我的VA网站2个），以及UB Jacobs School的其他部门的22个部门 医学和生物医学科学，以帮助他们进行职业发展。此外，我一直很活跃 参加ARVO全球指导计划，并在ASCB国际事务委员会任职。 总体而言，我的研究，教学和服务活动达到或超过了我的大学的学术标准 并且与VA HSR＆D的任务和Crado的跨切割临床优先事项完全一致。